Edinburgh’s Kynos Therapeutics reveals significant findings from trial of leading drug candidate

Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.